Funding Update from Algocell: $2.8M Pre-Seed to Accelerate AI Digital Twins for Bioprocess Optimization

Earlier this month Algocell, an Israel-based deep-tech startup, closed a USD 2.8 million pre-seed round. The investment was led by Good Company VC (GCVC) and includes a non-dilutive grant from the Israel Innovation Authority together with several sector-focused angel investors. As part of the transaction, GCVC partner Arnaud Lorie has joined our board of directors.

The proceeds will support team expansion, extension of the predictive capabilities of our AI-powered Digital Twin platform, and the launch of commercial pilot programs with manufacturers in food, agriculture, therapeutics, industrial materials, biofuels, and cosmetics.

We believe that building a robust and accurate digital asset that mirrors the biological system can significantly shorten the path to cost reduction, scale-up, and tech transfer to manufacturing units - processes that often delay industry progress by years. The same challenge repeats itself across all cell-based products, from precision-fermented dairy proteins to recombinant yeast strains engineered to produce human insulin.

For both existing and emerging products, the industry needs an approach that resolves core scale-up issues faster, drives costs down, and ultimately improves producer profitability.

About Algocell

Founded in 2023, Algocell is an AI-driven platform for optimizing bioprocess development and scale-up in cell-based manufacturing. Designed for both R&D and production teams, the platform enables faster experimentation, improved process control, and consistent product quality - using Machine Learning models that deliver insights from small datasets.

Algocell supports leading companies across cultivated meat, precision fermentation, and biopharma. Backed by investors including GCVC, the company brings together expertise in biology, engineering, and AI to modernize bioprocessing and accelerate the shift toward scalable, data-driven biomanufacturing.